What is Gilead Sciences's yeztugo — total revenues?

Gilead Sciences (GILD) reported yeztugo — total revenues of $166M in Q1 2026.

What does yeztugo — total revenues mean?

The total sales revenue generated by the Yeztugo product line.

How do you interpret yeztugo — total revenues?

An increase indicates strong market penetration, successful patient retention, or favorable pricing adjustments, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.

How does yeztugo — total revenues compare across companies?

Comparable to specific drug or therapeutic class revenue lines reported by other major biopharmaceutical companies, often benchmarked against market share in the HIV or infectious disease therapeutic categories.

Gilead Sciences GILD Yeztugo — Total revenues

Other product segments

Biktarvy

$3.36B+6.7%

Descovy

$807M+37.7%

Trodelvy

$402M+37.2%

Yescarta

$332M-14.0%

Sofosbuvir/Velpatasvir

$283M-18.2%

Genvoya

$264M-27.5%

Vemlidy

$237M-6.0%

Odefsey

$221M-21.4%

Veklury

$144M-52.3%

AmBisome

$138M-0.7%

Symtuza - Revenue share

$138M+21.1%

Livdelzi

$133M+233%

Other Liver Disease

$114M-5.8%

Tecartus

$75M-3.8%

Other HIV

$73M-19.8%

Other

$58M-17.1%

Royalty, contract and other revenues

$14M-74.1%

Similar metrics at other companies

INCYZYNYZ — Total revenues

$41.39M+1,276%

BIIBZURZUVAE — Total Revenue

$55.4M+100%

INCYOPZELURA — Total revenues

$143.02M+20.5%

INCYMINJUVI — Total revenues

$8.99M+87.0%

BIIBTYSABRI — Total Revenue

$441.5M+15.7%

JAZZVyxeos — Revenue from Contract with Customer, Excluding Assessed Tax

$26.6M-9.8%

Other financials

Income statement

See full

Revenue$7.0B+4.4%

Gross profit$5.5B+7.6%

Operating income$2.6B+15.6%

Net income$2.0B+53.7%

EPS (diluted)$1.61+54.8%

Balance sheet

See full

Cash & equivalents$7.6B-3.8%

Total debt$22.2B-11.1%

Total equity$23.5B+22.7%

Total assets$56.3B-0.3%

Cash flow

See full

Operating cash flow$2.5B+44.8%

CapEx$117.0M+12.5%

Free cash flow$2.4B+46.8%

Valuation

See full

Market cap$153.66B+23.8%

Enterprise value$168.2B+19.7%

P/E16.7×-4.1×

P/S5.2×+0.8×

Profitability

See full

Gross margin79.4%+1.1pp

Operating margin34.9%+6.3pp

Net margin31%+10.2pp

FCF margin34.4%+0.1pp

Returns & leverage

See full

Return on equity43.2%+10.7pp

Debt / equity0.9×-0.4×

Current ratio2×+0.6×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's yeztugo — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gilead Sciences's yeztugo — total revenues?: Gilead Sciences (GILD) reported yeztugo — total revenues of $166M in Q1 2026.
What does yeztugo — total revenues mean?: The total sales revenue generated by the Yeztugo product line.
How do you interpret yeztugo — total revenues?: An increase indicates strong market penetration, successful patient retention, or favorable pricing adjustments, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
How does yeztugo — total revenues compare across companies?: Comparable to specific drug or therapeutic class revenue lines reported by other major biopharmaceutical companies, often benchmarked against market share in the HIV or infectious disease therapeutic categories.